IBOV 170,888.18 ▼ 0.91% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.72▲ 0.91% USD/MXN18.64▲ 0.70% USD/CLP1,002▲ 0.67% USD/COP3,314▲ 0.34% USD/PEN3.40▲ 0.01% USD/ARS1,547▲ 0.21% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB11.59— 0.00% USD/DOP60.36▼ 0.38% USD/CRC442.56▼ 0.04% USD/GTQ7.64▼ 0.01% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69— 0.00% USD/TTD6.72▼ 0.44% EUR/BRL6.30▲ 0.75% BRENT 94.24 ▼ 1.67% WTI 87.67 ▼ 1.00% IRON ORE 161.91 — — COPPER 6.05 ▼ 0.49% GOLD 3,871 ▼ 0.40% SILVER 47.18 ▼ 3.79% SOY 1,226 ▼ 1.39% CORN 444.75 ▼ 0.17% WHEAT 590.00 ▼ 0.55% COFFEE 273.80 ▼ 1.74% SUGAR 18.24 ▼ 0.92% ORANGE JUICE 137.60 ▲ 0.95% COTTON 81.34 ▲ 3.25% COCOA 5,270 ▲ 2.95% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 170,888.18 ▼ 0.91% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.72 ▲ 0.92% USD/MXN 18.63 ▲ 0.66% USD/CLP 1,001 ▲ 0.64% USD/COP 3,314 ▲ 0.34% USD/PEN 3.41 ▲ 0.07% USD/ARS 1,547 ▲ 0.21% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 ▲ 2.15% USD/DOP 60.56 ▼ 0.05% USD/CRC 442.74 ▲ 1.24% USD/GTQ 7.64 ▼ 0.01% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.72 ▲ 2.12% EUR/BRL 6.30 ▲ 0.75% BRENT 94.24 ▼ 1.67% WTI 87.67 ▼ 1.00% IRON ORE 161.91 — — COPPER 6.05 ▼ 0.49% GOLD 3,871 ▼ 0.40% SILVER 47.18 ▼ 3.79% SOY 1,226 ▼ 1.39% CORN 444.75 ▼ 0.17% WHEAT 590.00 ▼ 0.55% COFFEE 273.80 ▼ 1.74% SUGAR 18.24 ▼ 0.92% ORANGE JUICE 137.60 ▲ 0.95% COTTON 81.34 ▲ 3.25% COCOA 5,270 ▲ 2.95% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

Brazil Business

Brazil Semaglutide Race Opens as Anvisa Clears Five Pens

By · · 4 min read
Brazil Semaglutide Race Opens as Anvisa Clears Five Pens
Photo: Marcosleal, CC BY-SA 3.0, via Wikimedia Commons

Brazil · Business

Key Facts

—Patent expiry Novo Nordisk’s semaglutide patent expired in March 2026, ending exclusivity for Ozempic and Wegovy in Brazil.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

—New registrations Anvisa registered five new semaglutide pens on July 29, 2026: Semavy, Owozy, Seemasun, Zempneo, and Orsema, joining EMS’s earlier Ozivy.

—Regulatory classification Under Brazilian law these are new synthetic semaglutide analogs, not technically generics, though they will compete on price.

—First to market Hypera Pharma’s Semavy, made with India’s Sun Pharma, is expected to be the first new pen to reach pharmacy shelves, in roughly two months.

—Pricing estimates Market sources expect new pens to launch at roughly R$500-R$600 (~US$98-US$118), around 30% below current Ozempic prices.

Brazil semaglutide generics competition has intensified sharply after the country’s health regulator Anvisa registered five new synthetic semaglutide pens on July 29, 2026, ending Danish pharmaceutical giant Novo Nordisk’s years-long monopoly on blockbuster diabetes and obesity treatments Ozempic and Wegovy.

The Patent Cliff and What It Unlocks

Novo Nordisk’s Brazilian semaglutide patent expired in March 2026, opening the door for domestic and international drugmakers to launch rival products. The originator’s two brands had dominated the market completely, with Ozempic retailing between R$825 and just over R$1,000 (~US$162-US$196) depending on dosage, and the higher-dose obesity treatment Wegovy reaching around R$2,500 (~US$490) for the 2.4 mg presentation.

Brazil Semaglutide Race Opens as Anvisa Clears Five Pens
A semaglutide injector pen. Photo: Wilfredor, CC BY-SA 4.0, via Wikimedia Commons

Six New Semaglutide Pens Now Registered

Anvisa registered five new semaglutide pens on July 29, 2026: Semavy from Hypera Pharma, Owozy from Avita Care in partnership with Sandoz and Europe’s Adalvo, Seemasun from Sun Farmaceutica, Zempneo from Brainfarma, and Orsema from Ranbaxy. These join EMS’s Ozivy, which was registered earlier, immediately after the patent expiry, bringing the total to six new semaglutide products in Brazil since exclusivity ended.

Hypera’s Semavy Expected First to Pharmacies

Hypera Pharma’s Semavy, developed via its Mantecorp brand and manufactured with India’s Sun Pharma, is expected to be the first of the newly registered pens to reach pharmacy shelves, in roughly two months. The product will enter a market where Ozivy, from Brazilian pharmaceutical company EMS, was the first synthetic analog to secure Anvisa registration, published on May 26, 2026.

What This Means for Patients

The arrival of competition should significantly reduce out-of-pocket costs for Brazil’s large population of semaglutide users. The drug is prescribed for both type 2 diabetes management and obesity treatment, with Anvisa having approved the obesity indication in January 2023. That dual-use profile has driven explosive demand growth, making affordability a pressing public health issue.

Investor Implications and Market Dynamics

For investors tracking Latin American healthcare, the Brazilian semaglutide opening mirrors similar post-patent races seen in other major pharmaceutical markets. Domestic champions like EMS and Hypera Pharma stand to gain significant market share, while Sandoz’s entry via Owozy signals international interest in capturing a slice of Brazil’s growing GLP-1 receptor agonist market.

Regulatory Landscape and Next Steps

Anvisa has demonstrated clear intent to accelerate competition, prioritizing semaglutide applications amid strong market interest. The agency also recently mandated prescription retention requirements for dispensing semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, and lixisenatide, tightening controls on GLP-1 medications amid concerns about off-label cosmetic use.

Frequently Asked Questions

Are the new semaglutide products in Brazil true generics?

No. Under Brazilian law these are not technically generics because semaglutide is a complex molecule. Anvisa classifies them as new medicines using synthetic versions of the semaglutide molecule, though they will compete like generics on price.

How much cheaper will the new semaglutide pens be?

Market estimates suggest launch prices around R$500-R$600 (~US$98-US$118), roughly 30 percent below current Ozempic prices of R$825-R$1,000 (~US$162-US$196). Official CMED maximum prices had not been published at the time of reporting.

Which new semaglutide pen will reach pharmacies first?

Hypera Pharma’s Semavy, developed via its Mantecorp brand and manufactured with India’s Sun Pharma, is expected to be the first of the newly registered pens to reach pharmacy shelves, in roughly two months. EMS’s Ozivy was registered earlier and may already be available.

RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Sources: Anvisa; Novo Nordisk; Hypera Pharma.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.